Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
 

Myelodysplastic Syndromes (MDS) Clinical Trials

A listing of Myelodysplastic Syndromes (MDS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (145) clinical trials

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) After Hypomethylating Agent-Failure

This is a Phase 1b, dose-ranging, open-label, multicenter study designed to evaluate the safety and pharmacokinetics of venetoclax as a single-agent and in combination with azacitidine in participants with higher-risk Myelodysplastic Syndromes (MDS) after Hypomethylating Agent (HMA)-Failure.

Phase

iCare for Cancer Patients

As part of normal clinical care, subjects will undergo peripheral blood draws and biopsies for disease assessment of their cancer. In cases of hematological malignancies, bone marrow aspiration & biopsy are routinely performed. As part of this project, the following will be done to the samples collected and with clinical ...

Phase N/A

Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Myelodysplastic Syndrome Low Risk

Patients with a matched donor (8/8 at molecular level unrelated donor or matched sibling) received an allogeneic hematopoietic stem cell transplantation. Patients without a matched donor received the best available treatment. All patients will be followed at least 36 months or until the end of the study.

Phase N/A

The Prospective Collection Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen

To provide the IRB approved mechanism for the prospective collection, analysis and reporting of data on patients who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated ...

Phase N/A

Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML

ARM A: DECITABINE (DAC) Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Treatment will be delayed at the discretion of the investigator (up to D56) for febrile neutropenia ( 38.5C; absolute neutrophil count [ANC], < 1,000/L), clinical and/or microbiologic infection with grade ...

Phase

A Study Evaluating Venetoclax in Combination With Azacitidine in Subjects With Treatment-Na ve Higher-Risk Myelodysplastic Syndromes (MDS)

This is a Phase 1b, open-label, non-randomized, multicenter, dose-finding study evaluating venetoclax in combination with azacitidine in subjects with treatment-nave higher-risk MDS comprising a dose-escalation portion and a safety expansion portion.

Phase

A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome

The dose-confirming part of this study, comprising at least 10 patients is designed as a single center, prospective, single arm, open label in patients who have failed or are unresponsive to Azacitidine (AZA) or Decitabine (they may also have additionally failed an Erythropoiesis Stimulating Agent (ESA) followed by a dose ...

Phase

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Evaluate the safety and efficacy of CC-486 in Subjects with Myelodysplastic Syndromes who failed to achieve an objective response post iHMA treatment Reason for removing the Combo arm: Due to difficulties with dose-finding, the durvalumab plus CC-486 combination arm is closed to enrollment

Phase

Transplantation of Ex Vivo Expanded UCB-derived Stem & Progenitor Cells vs. Unmanipulated UCB for HM Patients

Successful blood and marrow transplantation (BMT) requires the infusion of a sufficient number of hematopoietic stem/progenitor cells (HSPCs), capable of both homing to the bone marrow and regenerating a full array of hematopoietic cell lineages with early and late repopulating ability in a timely fashion. A major drawback of Umbilical ...

Phase

A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies

This is a multicenter, open label, Phase 1 dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies. Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once ...

Phase